Preview

Rational Pharmacotherapy in Cardiology

Advanced search

TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER. (Part 1)

https://doi.org/10.20996/1819-6446-2013-9-2-138-142

Full Text:

Abstract

According to the data from PROGNOZ IBS register drugs with proven efficacy in secondary prevention of cardiovascular complications (antiplatelets, β-blockers, ACE inhibitors, statins) were not often prescribed in patients with stable ischemic heart disease prior to hospitalization. Significant improvement of the treatment quality was found during the cardiology hospital stay. The prescription rate of ACE inhibitors increased from 20% to 84.4%, statins - from 10% to 85.5%, β-blockers - from 20% to 91%, acetylsalicylic acid - from 74% to 96%. However, some drugs (statins) have been used in inadequate doses. Low-density lipoprotein level <2.5 mmol/L was achieved at discharge only in 6.3% of patients.

About the Authors

S. N. Tolpygina
State Research Centre for Preventive Medicine, Moscow
Russian Federation


Yu. N. Polyanskaya
State Research Centre for Preventive Medicine, Moscow
Russian Federation


S. Yu. Martsevich
State Research Centre for Preventive Medicine, Moscow
Russian Federation


References

1. World Health Organization. Preventing chronic diseases: A vital investment. Available from: http:// www.ho.int/chp/chronic_disease _report/contents/en/ index. html. Date of access 10/04/2013.

2. Demographic year-book of Russia, 2010. Statistical Collection. Moscow: Rosstat 2011. Russian (Демографический ежегодник России, 2010. Статистический Сборник Росстат. M.: Росстат; 2011).

3. ISIS–2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokianse, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS02. Lancet 1988; 332: 349–360.

4. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: ISIS-4. A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspect acute myocardial infarction. Lancet 1995; 346: 669–85.

5. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet 1994: 344: 1383–1389.

6. Schomig A., Neumann F. J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. (ISAR). N Engl J Med 1996;334:1084–9.

7. Sever PS, Dahlof B, Poulter NR, et al for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149–1158.

8. Sever P.S., Poulter N.R., Dahlof B. et al. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lopid-Lowering Arm (ASCOT-LLA). Am J Cardiol 2005; 96 (5 suppl): 39–44F.

9. Dahlof B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an attihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895–906.

10. Shepherd L, Blauw GJ, Murphy MB, et al. PROSPER study group. PROspective study of pravastatin in the elderly at risk. Pravastatin in elederly individuals at risk vascular disease (PROSPER): a randomised controlled trial. Lancet 2002: 360; 1623–1630.

11. Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329–39.

12. Stevens VJ, Obarzanek E, Cook NR, et al. Trials of Hypertension Prevention-II. Ann Intern Med 2001; 134: 1–11.

13. Swedberg K, Held P, Kjekshus J et al. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678–84.

14. The Acute Infarction Ramipril Effiicacy (AIRE) Study Investigators: effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821.

15. The BHAT research group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247:1707–14.

16. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.

17. The coronary heart disease risk map of Europe. The 1-st Report of the WHO ERICA Project. Eur Heart J 1988; 9 (Suppl 1): 1–36.

18. The EURopean trial On reduction of cardiac events whit Perindopril in stable coronary Artery disease investigators. Efficacy of perindoprili in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782–8.

19. The Heart Outcomen Prevention Evaluation Study investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342(3): 145–53.

20. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349–135.

21. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial the SAVE Investigators. N Engl J Med 1992; 327: 669–77.

22. Pfeffer AM. Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Association Scientific Sessions 2003; November 9–12, 2003; Orlando, Florida. Plenary Session III: Late Breaking Clinical Trials.

23. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–52.

24. Yusuf S., Islam S., Chow C.K. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378(9798):1231–43.

25. Oganov R. G., Pogosova G. V., Koltunov I.E. et al. RELIF – Regular Treatment And prevention – a key to situation improvement with cardiovascular diseases in Russia: results Russian multicenter research. Part I. Kardologiia 2007; 47(5): 58–66. (Оганов Р.Г., Погосова Г.В., Колтунов И.Е., и др. РЕЛИФ – Регулярное Лечение И проФилактика – ключ к улучшению ситуации с сердечно-сосудистыми заболеваниями в России: результаты российского многоцентрового исследования Часть I. Кардиология 2007; 47(5): 58–66).

26. Oganov R. G., Pogosova G. V., Koltunov I.E. et al. RELIF – Regular Treatment And prevention – a key to situation improvement with cardiovascular diseases in Russia: results of the Russian multicenter research Part II. Kardologiia 2007; 47(11): 30–39. (Оганов Р.Г., Погосова Г.В., Колтунов И.Е., и др. РЕЛИФ – Регулярное Лечение И проФилактика – ключ к улучшению ситуации с сердечно-сосудистыми заболеваниями в России: результаты российского многоцентрового исследования Часть II. Кардиология 2007; 47(11): 30–39).

27. Oganov R.G., Pogosova G.V., Koltunov I.E. etc. RELIF – Regular Treatment And prevention – a key to situation improvement with cardiovascular diseases in Russia: results of the Russian multicenter research. Part III. Kardologiia 2008; 48(4): 46–53 (Оганов Р.Г., Погосова Г.В., Колтунов И.Е., и др. РЕЛИФ – Регулярное Лечение И проФилактика – ключ к улучшению ситуации с сердечно-сосудистыми заболеваниями в России: результаты российского многоцентрового исследования. Часть III. Кардиология 2008; 48(4): 46–53).

28. Oganov R.G., Fitilev S.B., Lepakhin V.K. et al. Assessment of implementation of recommendations about secondary prevention of cardiovascular diseases at the patients who have had a myocardial infarction. Kardiovaskulyarnaya Terapiya i Profilaktika 2009; 8(4):71–75. (Оганов Р.Г., Фитилев С.Б., Лепахин В.К. и др. Оценка выполнения рекомендаций по вторичной профилактике сердечно-сосудистых заболеваний у пациентов, перенесших инфаркт миокарда. Кардиоваскулярная Терапия и Профилактика 2009;8(4):71–75).

29. Susekov A.V., Zubareva M.Yu, Deev A.D, et al. Main results of the Moscow Research on Statines (to Moscow Statin Survey, MSS). Serdtse 2006; (6) : 324–328. Russian (Сусеков А В, Зубарева М.Ю, Деев А.Д, и др. Основные результаты Московского Исследования по Статинам (Moscow Statin Survey, MSS). Сердце 2006;(6): 324–328).

30. Martsevich S.Y., Oganisyan N.S., Dmitrieva N.A., Klimakov A.V. Condition of diagnostics and treatment of an arterial hypertension according to poll of doctors of Volgograd and the Volgograd region. Rational Pharmacother Card 2005; (2):32–36. Russian (Марцевич С.Ю., Оганисян Н.С., Дмитриева Н.А., Климаков А.В. Состояние диагностики и лечения артериальной гипертонии по данным опроса врачей Волгограда и Волгоградской области. РФК 2005;(2):32–36).

31. Oganov R.G., Maslennikova G.Y. Cardiovascular diseases in the Russian Federation in the second half of the 20th century: tendencies, possible reasons, prospects. Kardiologiia 2000; (6):4–8. Russian (Ога- нов Р.Г., Масленникова Г.Я. Сердечно-сосудистые заболевания в Российской Федерации во вто- рой половине 20 столетия: тенденции, возможные причины, перспективы. Кардиология 2000; (6): 4–8).

32. Neutel J.M., Smith D.H. Improving patient compliance: a major goal in the management of hypertension. J Clin Hypertens (Greenwich) 2003; 5(2):127–132.

33. Leibovitz E, Hertsog D, Oren S, et al. Lack of treatment continuance: an obstacle for controlling blood pressure. Harefuah 2005; 144(7): 467–70, 528, 527.

34. Chabot I, Moisan J, Gregoire J.P, et al. Pharmacist intervention program for control of hypertension. Ann Pharmacother 2003; 37(9): 1186–93.

35. Shalnova S.A., Deev A.D., Karpov Yu.A. Arterial hypertension and coronary heart disease in real practice of the cardiologist. Kardiovaskulyarnaya Terapiya i Profilaktika 2006; 5(2): 73–80. Russian (Шальнова С.А., Деев А.Д., Карпов Ю.А. Артериальная гипертония и ишемическая болезнь сердца в реальной практике врача-кардиолога. Кардиоваскулярная Терапия и Профилактика 2006; 5(2): 73–80).

36. Shalnova S.A., Deev A.D. "Research lessons the OSCAR – epidemiology and features of therapy of patients of high risk in real clinical practice 2005–2006". Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6(1):47–53. Russian (Шальнова С.А., Деев A.Д. ≪Уроки исследования ОСКАР – эпидемиология и особенности терапии пациентов высокого риска в реальной клинической практике 2005–2006г≫. Кардиоваскулярная Терапия и Профилактика 2007; 6(1):47–53).

37. Shalnova S.A., Deev A.D. Vikhireva O.V. Arterial hypertension eyes of ambulatory patients. First results of the research GARANT. Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6(5):30–33. Russian (Шальнова С.А., Деев А.Д., Вихирева О.В. Артериальная гипертония глазами амбулатор- ных пациентов. Первые результаты исследования ГАРАНТ. Кардиоваскулярная Терапия и Профилактика 2007;6(5):30–33.)

38. Gofman E.A., Martsevich S.Yu., Deev A.D., et al. First results of the study CHD PROGNOSIS. Klinitsist 2012,1:58–64. Russian (Гофман Е.А., Марцевич С.Ю., Деев А.Д., и др. Первые результаты исследования ПРОГНОЗ ИБС. Клиницист 2012,1:58–64).

39. Tolpygina S.N., Martsevich S.Yu., Gofman E.A., et al. The study "CHD PROGNOSIS" – experience of creation of the register for an assessment of outcomes of chronically proceeding CHD. Kardiovaskulyarnaya Terapiya i Profilaktika 2013;(1):32–39. Russian (Толпыгина С.H., Марцевич С.Ю., Гофман Е.А., Малышева А.М., Полянская Ю.Н., Деев А.Д. Исследование ≪ПРОГНОЗ ИБС≫ – опыт создания регистра для оценки исходов хронически протекающей ИБС. Кардиоваскулярная Терапия и Профилактика 2013;1:32–39).

40. Panchenko E.P., Belenkov Yu.N. The characteristic and outcomes aterotrombosis at outpatients in the Russian Federation (on materials of the international REACH register). Kardiologiia 2008;(2):17–24. Russian (Панченко Е.П., Беленков Ю.Н. Характеристика и исходы атеротромбоза у амбулаторных больных в Российской Федерации (по материалам международного регистра REACH). Кардиология 2008; (2): 17–24).

41. Kotseva K., Wood D., De Backer G., et al. EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from twenty-two European countries. Eur J Cardiovasc Prev Rehabil 2009;16(2):121–37.

42. Oganov R.G., Lepakhin V.K., Fitilev S.B. etc. Features of diagnostics and therapy of stable stenocardia in the Russian Federation (the international research ATP-Angina Treatment Pattern). Kardiologiia 2003; (5): 9–15. Russian (Оганов Р.Г., Лепахин В.К., Фитилев С.Б.. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное ис- следование ATP–Angina Treatment Pattern).


For citation:


Tolpygina S.N., Polyanskaya Y.N., Martsevich S.Yu. TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER. (Part 1). Rational Pharmacotherapy in Cardiology. 2013;9(2):138-142. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-2-138-142

Views: 455


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)